Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

What is the most Silicon Valley thing about your morning routine? Zoë, you go first. Zoë Schiffer: Pretty much the first ...

Me just dropped some major news in a tough year for the genetic testing company. After months of financial challenges, data ...

CEO Anne Wojcicki has said she intends to take the company private and is not considering third-party takeover proposals.

The genetic testing company 23andMe hasn't been doing so hot lately, watching its share price plummet more than 70% this year ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...

CEO Anne Wojcicki, who holds roughly half of the voting power, is attempting to take the company private. In September, seven ...

Home genetics company 23andMe continues to struggle as demand for casual gene tracing declines. On Monday, the company announced that it has decided on a restructuring ...

Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...

Regarding its workforce reduction, which will total 200 employees, CEO Anne Wojcicki called the layoffs a “difficult but necessary” step to keep the company alive. “We are taking these difficult but ...